845 related articles for article (PubMed ID: 28718070)
1. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.
Lozano Martínez AJ; Moreno Cano R; Escobar Páramo S; Salguero Aguilar R; Gonzalez Billalabeitia E; García Fernández R; De La Fuente Muñoz I; Romero Borque A; Porras Martínez M; Lopez Soler F; Cardenas Cánovas E; Ortega Martín I
Clin Transl Oncol; 2017 Dec; 19(12):1531-1536. PubMed ID: 28718070
[TBL] [Abstract][Full Text] [Related]
2. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Onal C; Sedef AM; Kose F; Oymak E; Guler OC; Sumbul AT; Aksoy S; Akkus Yildirim B; Besen AA; Muallaoglu S; Mertsoylu H; Ozyigit G
Future Oncol; 2019 May; 15(13):1469-1479. PubMed ID: 30977383
[TBL] [Abstract][Full Text] [Related]
3. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
[TBL] [Abstract][Full Text] [Related]
4. Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer.
Lian L; Xia YY; Zhou C; Shen XM; Li XL; Han SG; Zheng Y; Mao ZQ; Gong FR; Wu MY; Chen K; Tao M; Li W
Cancer Biomark; 2015; 15(6):899-907. PubMed ID: 26444485
[TBL] [Abstract][Full Text] [Related]
5. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664
[TBL] [Abstract][Full Text] [Related]
6. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
Kawahara T; Kato M; Tabata K; Kojima I; Yamada H; Kamihira O; Tsumura H; Iwamura M; Uemura H; Miyoshi Y
BMC Cancer; 2020 Sep; 20(1):919. PubMed ID: 32977754
[TBL] [Abstract][Full Text] [Related]
7. Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
Chong W; Zhang Z; Luo R; Gu J; Lin J; Wei Q; Li B; Myers R; Lu-Yao G; Kelly WK; Wang C; Yang H
BMC Cancer; 2021 Jun; 21(1):655. PubMed ID: 34078304
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
[No Abstract] [Full Text] [Related]
9. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
11. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
13. Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?
Solmaz Medeni S; Acar C; Olgun A; Acar A; Seyhanlı A; Taskıran E; Sevindik OG; Alacacıoglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Transplant; 2018 Sep; 32(9):e13359. PubMed ID: 30053318
[TBL] [Abstract][Full Text] [Related]
14. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; de Bono JS; Joshua AM
Ann Oncol; 2014 Mar; 25(3):657-662. PubMed ID: 24458472
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.
Loubersac T; Nguile-Makao M; Pouliot F; Fradet V; Toren P
Eur Urol Oncol; 2020 Jun; 3(3):298-305. PubMed ID: 31411963
[TBL] [Abstract][Full Text] [Related]
16. Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.
Nieblas-Toscano D; Arenas-Bonilla AJ; Flores-Martín JF; Gutiérrez-Tejero F; Velarde-Muñoz C; Ramos-Alaminos CI; Salas-Moreno MC; Galisteo-Moya R; Moreno-Jiménez J
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):164-171. PubMed ID: 32035807
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of pre-operative neutrophil/lymphocyte ratio, monocyte count, mean platelet volume, and platelet/lymphocyte ratio in endometrial cancer.
Temur I; Kucukgoz Gulec U; Paydas S; Guzel AB; Sucu M; Vardar MA
Eur J Obstet Gynecol Reprod Biol; 2018 Jul; 226():25-29. PubMed ID: 29804024
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide.
Pisano C; Tucci M; DI Stefano RF; Turco F; Samuelly A; Bungaro M; Vignani F; Tarenghi F; Scagliotti GV; DI Maio M; Buttigliero C
Minerva Urol Nephrol; 2021 Dec; 73(6):803-814. PubMed ID: 33781017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
